𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The immune response of low dose recombinant DNA hepatitis B vaccine in teenagers in Singapore

✍ Scribed by R. Guan; H.H. Tay; I. Yap; R. Smith; L.H. Tan

Book ID
103363572
Publisher
Elsevier Science
Year
1990
Tongue
English
Weight
240 KB
Volume
84
Category
Article
ISSN
0035-9203

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Very low dose hepatitis B vaccination in
Very low dose hepatitis B vaccination in the newborn: Anamnestic response to booster at four years
✍ Dr. C. D. Moyes; A. Milne; J. Waldon πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 236 KB

## Abstract Seventy‐eight children who had received three very low doses (1 or 2 ΞΌg) of Merck, Sharp, and Dohme (MSD) plasma‐derived vaccine (PDV) in early infancy were followed to approximately four years of age. Of the 70 who had responded to the initial course of vaccine with measurable anti‐HBs

Immunoprophylaxis of perinatal transmiss
Immunoprophylaxis of perinatal transmission of the hepatitis B virus: Efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low-prevalence area
✍ J. I. Esteban; J. Genesca; R. Esteban; J. M. Hernandez; G. Seijo; M. Buti; R. Mu πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 English βš– 686 KB

One hundred eleven newborn infants born of Spanish hepatitis B surface antigen (HBsAg) carrier mothers were consecutively assigned to one of three treatment groups. Group A was treated with three or four doses of hepatitis B immune globulin (HBIG) in one of three different schedules. Group B receive

Twelve-year follow-up of a prospective r
Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children
✍ Man-Fung Yuen; Wei-Ling Lim; Chi-Chung Cheng; Shiu-Kam Lam; Ching-Lung Lai πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 49 KB

A total of 318 children were prospectively randomized in group 1 with two 5-g doses of recombinant vaccine given at 0 and 1 month; in group 2 with three 5-g doses of recombinant vaccine given at 0, 1, and 6 months; or in group 3 with three doses of plasma-derived vaccine given at 0, 1, and 6 months.